Home » Microscopy » RareCyte CyteFinder II CTCs and Rare Cell Detection Imaging Picking
RareCyte enables practical deployment of circulating tumor cell (CTC) and rare cell-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single cell isolation.
https://link.springer.com/article/10.1007/s10549-022-06585-5
CTC enumeration was demonstrated to be prognostic of outcome nearly two decades ago3. Advances in CTC technology now allow interrogation of cancer phenotypes and likelihood they might be responsive to therapeutics.
CyteFinder® II Instruments are high-speed, whole slide imaging systems with options for multiplexed liquid biopsy and tissue spatial analysis. IF, H&E, and IHC modes for imaging blood smears, tissue sections, and cytology preparation including fine needle aspirates.
Integrated machine learning algorithm detects and rank orders candidate cells for user review. Tissue option for digital pathology on the CyteFinder II Instrument. CytePicker® Retrieval Module enables single cell or tissue micro-region retrieval from any location on the slide.
Accurate CTC detection is critical in the recovery of useful, quantitative data from patient blood. A research article published in Frontiers in Oncology describes the AccuCyte process for CTC isolation and CyteFinder II’s immunofluorescence staining and imaging, together providing a reliable and accurate workflow at > 95% when compared to recovery rates using density or lysis-based processes.
Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging
Yeo D, Kao S, Gupta R, et al.
University of Sydney, Sydney, Australia
Learn how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly and the platform added to a global clinical trial for further evaluation in collaboration with a CRO.
Speakers:
Please fill out our form ,and we’ll get in touch shortly